OncoMatch/Clinical Trials/NCT07007117
PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma
Is NCT07007117 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies PHOX2B PC-CAR T Cells for refractory neuroblastoma.
Treatment: PHOX2B PC-CAR T Cells — This is a first in human dose escalation trial to determine the safety of administering PHOX2B PC-CAR T cells in patients with advanced, high-risk neuroblastoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroblastoma
Lab requirements
Kidney function
age-adjusted serum creatinine ≤1.5 ULN for age
Liver function
Total bilirubin ≤ 1.5 x ULN (exception: ≤ 3 ULN for Gilbert's Disease or liver metastases); ALT ≤ 3.0 ULN (exception: ≤ 5 x ULN for liver metastases); AST ≤ 3.0 ULN (exception: ≤ 5 x ULN for liver metastases)
Cardiac function
LVSF ≥28% or LVEF ≥ 50% confirmed by Echo, or adequate ventricular function documented by scan or cardiologist
Liver Function: Total bilirubin ≤ 1.5 x ULN (exception: ≤ 3 ULN for Gilbert's Disease or liver metastases); ALT ≤ 3.0 ULN (exception: ≤ 5 x ULN for liver metastases); AST ≤ 3.0 ULN (exception: ≤ 5 x ULN for liver metastases). Renal Function: age-adjusted serum creatinine ≤1.5 ULN for age. Cardiac Function: LVSF ≥28% or LVEF ≥ 50% confirmed by Echo, or adequate ventricular function documented by scan or cardiologist.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify